UA112425C2 - ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ - Google Patents
ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУInfo
- Publication number
- UA112425C2 UA112425C2 UAA201308896A UAA201308896A UA112425C2 UA 112425 C2 UA112425 C2 UA 112425C2 UA A201308896 A UAA201308896 A UA A201308896A UA A201308896 A UAA201308896 A UA A201308896A UA 112425 C2 UA112425 C2 UA 112425C2
- Authority
- UA
- Ukraine
- Prior art keywords
- inhibitors
- tyrosininas
- typininase
- indasol
- imidaso
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42254710P | 2010-12-13 | 2010-12-13 | |
| PCT/US2011/064549 WO2012082689A1 (en) | 2010-12-13 | 2011-12-13 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA112425C2 true UA112425C2 (uk) | 2016-09-12 |
Family
ID=45478484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201308896A UA112425C2 (uk) | 2010-12-13 | 2011-12-13 | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9174981B2 (https=) |
| EP (1) | EP2651939B1 (https=) |
| JP (3) | JP5868996B2 (https=) |
| KR (1) | KR101974665B1 (https=) |
| CN (3) | CN103347882B (https=) |
| AU (3) | AU2011344001B2 (https=) |
| BR (1) | BR112013014854B1 (https=) |
| CA (2) | CA2821712C (https=) |
| CL (1) | CL2013001712A1 (https=) |
| CO (1) | CO6751248A2 (https=) |
| CR (1) | CR20130349A (https=) |
| DK (1) | DK2651939T3 (https=) |
| ES (1) | ES2540996T3 (https=) |
| HR (1) | HRP20150571T1 (https=) |
| HU (1) | HUE025416T2 (https=) |
| IL (1) | IL226911A (https=) |
| ME (1) | ME02172B (https=) |
| MX (1) | MX2013006763A (https=) |
| MY (1) | MY172110A (https=) |
| NZ (1) | NZ613235A (https=) |
| PH (1) | PH12013501221A1 (https=) |
| PL (1) | PL2651939T3 (https=) |
| PT (1) | PT2651939E (https=) |
| RS (1) | RS54070B1 (https=) |
| RU (1) | RU2591195C2 (https=) |
| SG (1) | SG191129A1 (https=) |
| SI (1) | SI2651939T1 (https=) |
| SM (1) | SMT201500165B (https=) |
| TW (1) | TWI527813B (https=) |
| UA (1) | UA112425C2 (https=) |
| UY (1) | UY33801A (https=) |
| WO (1) | WO2012082689A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102822170B (zh) * | 2009-12-21 | 2014-12-10 | 阵列生物制药公司 | 作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物 |
| SI2651939T1 (sl) * | 2010-12-13 | 2015-07-31 | Array Biopharma, Inc. | SUBSTITUIRANE N-(1H-INDAZOL-4-IL)IMIDAZO(1,2-a)PIRIDIN-3-KARBOKSAMIDNE SPOJINE KOT INHIBITORJI RECEPTORSKE TIROZINSKE KINAZE TIPA III |
| GB201315486D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CN104496891A (zh) * | 2014-12-06 | 2015-04-08 | 哈尔滨工业大学 | 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法 |
| CN104974078A (zh) * | 2015-06-25 | 2015-10-14 | 黄荣辉 | 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法 |
| WO2017024408A1 (en) | 2015-08-11 | 2017-02-16 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| CN108137539B (zh) | 2015-08-12 | 2022-01-11 | 尼奥迈德研究所 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| ES2895904T3 (es) * | 2015-11-02 | 2022-02-23 | Genase Therapeutics B V | Tetrahidroindazoles y usos médicos de los mismos |
| CN105198799A (zh) * | 2015-11-03 | 2015-12-30 | 江苏梦得电镀化学品有限公司 | 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法 |
| WO2017127930A1 (en) | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| MX383856B (es) | 2016-06-14 | 2025-03-14 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
| CN106187899B (zh) * | 2016-06-28 | 2019-07-16 | 绍兴文理学院 | 一种氟代氮杂芳烃的合成方法 |
| WO2018019291A1 (en) * | 2016-07-29 | 2018-02-01 | The Hong Kong University Of Science And Technology | C(sp3)-c(sp2) cross-coupling reaction of organozinc reagents and heterocyclic (pseudo)halides |
| EP3535243B1 (en) | 2016-11-04 | 2021-12-15 | Auckland Uniservices Limited | Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer |
| CA3041986A1 (en) * | 2016-11-28 | 2018-05-31 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
| WO2018213665A1 (en) | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| FI3658552T3 (fi) | 2017-07-28 | 2023-11-16 | Yuhan Corp | Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa |
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| CN111410654B (zh) * | 2019-01-19 | 2022-05-17 | 江苏新元素医药科技有限公司 | 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成 |
| TWI841671B (zh) | 2019-01-24 | 2024-05-11 | 日商第一三共股份有限公司 | 具有取代基之脲化合物 |
| TWI759829B (zh) | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
| CN114667289B (zh) | 2019-09-18 | 2025-08-26 | 武田药品工业有限公司 | 杂芳基血浆激肽释放酶抑制剂 |
| EP4031547B1 (en) | 2019-09-18 | 2024-07-17 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof |
| PH12022551401A1 (en) | 2019-12-09 | 2023-08-23 | Syndax Pharmaceuticals Inc | Antibodies for the treatment of chronic graft versus host disease |
| TW202542157A (zh) * | 2024-01-04 | 2025-11-01 | 大陸商上海翰森生物醫藥科技有限公司 | 多環類衍生物抑制劑、其製備方法和應用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| NZ537156A (en) | 2002-05-23 | 2007-06-29 | Cytopia Pty Ltd | Kinase inhibitors |
| CN101679409B (zh) * | 2006-12-22 | 2014-11-26 | Astex治疗学有限公司 | 双环杂环衍生化合物、其医药组合物和其用途 |
| EP2137184B1 (en) * | 2007-04-03 | 2013-05-08 | Array Biopharma, Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| FR2925901B1 (fr) | 2008-01-02 | 2011-03-04 | Sanofi Aventis | DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| JP5502076B2 (ja) * | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規化合物 |
| TW201105669A (en) * | 2009-07-30 | 2011-02-16 | Irm Llc | Compounds and compositions as Syk kinase inhibitors |
| CN102822170B (zh) * | 2009-12-21 | 2014-12-10 | 阵列生物制药公司 | 作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物 |
| JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| SI2651939T1 (sl) | 2010-12-13 | 2015-07-31 | Array Biopharma, Inc. | SUBSTITUIRANE N-(1H-INDAZOL-4-IL)IMIDAZO(1,2-a)PIRIDIN-3-KARBOKSAMIDNE SPOJINE KOT INHIBITORJI RECEPTORSKE TIROZINSKE KINAZE TIPA III |
| CN102250246A (zh) * | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
-
2011
- 2011-12-13 SI SI201130508T patent/SI2651939T1/sl unknown
- 2011-12-13 UA UAA201308896A patent/UA112425C2/uk unknown
- 2011-12-13 MX MX2013006763A patent/MX2013006763A/es active IP Right Grant
- 2011-12-13 CA CA2821712A patent/CA2821712C/en not_active Expired - Fee Related
- 2011-12-13 HU HUE11808427A patent/HUE025416T2/en unknown
- 2011-12-13 PT PT118084276T patent/PT2651939E/pt unknown
- 2011-12-13 DK DK11808427.6T patent/DK2651939T3/en active
- 2011-12-13 SG SG2013045349A patent/SG191129A1/en unknown
- 2011-12-13 RU RU2013132758/04A patent/RU2591195C2/ru active
- 2011-12-13 RS RS20150446A patent/RS54070B1/sr unknown
- 2011-12-13 JP JP2013544674A patent/JP5868996B2/ja not_active Expired - Fee Related
- 2011-12-13 US US13/994,048 patent/US9174981B2/en not_active Expired - Fee Related
- 2011-12-13 UY UY0001033801A patent/UY33801A/es not_active Application Discontinuation
- 2011-12-13 CN CN201180067342.XA patent/CN103347882B/zh not_active Expired - Fee Related
- 2011-12-13 PH PH1/2013/501221A patent/PH12013501221A1/en unknown
- 2011-12-13 CN CN201811311712.XA patent/CN109608449A/zh active Pending
- 2011-12-13 NZ NZ61323511A patent/NZ613235A/en not_active IP Right Cessation
- 2011-12-13 ES ES11808427.6T patent/ES2540996T3/es active Active
- 2011-12-13 TW TW100146108A patent/TWI527813B/zh not_active IP Right Cessation
- 2011-12-13 ME MEP-2015-98A patent/ME02172B/me unknown
- 2011-12-13 EP EP11808427.6A patent/EP2651939B1/en active Active
- 2011-12-13 KR KR1020137018492A patent/KR101974665B1/ko not_active Expired - Fee Related
- 2011-12-13 AU AU2011344001A patent/AU2011344001B2/en not_active Ceased
- 2011-12-13 CA CA3027814A patent/CA3027814A1/en not_active Abandoned
- 2011-12-13 BR BR112013014854-3A patent/BR112013014854B1/pt not_active IP Right Cessation
- 2011-12-13 HR HRP20150571TT patent/HRP20150571T1/hr unknown
- 2011-12-13 WO PCT/US2011/064549 patent/WO2012082689A1/en not_active Ceased
- 2011-12-13 MY MYPI2013700991A patent/MY172110A/en unknown
- 2011-12-13 PL PL11808427T patent/PL2651939T3/pl unknown
- 2011-12-13 CN CN201610248287.9A patent/CN105924437B/zh not_active Expired - Fee Related
-
2013
- 2013-06-13 IL IL226911A patent/IL226911A/en active IP Right Grant
- 2013-06-13 CL CL2013001712A patent/CL2013001712A1/es unknown
- 2013-07-15 CR CR20130349A patent/CR20130349A/es unknown
- 2013-07-15 CO CO13167580A patent/CO6751248A2/es active IP Right Grant
-
2015
- 2015-07-08 SM SM201500165T patent/SMT201500165B/xx unknown
- 2015-09-18 US US14/858,029 patent/US9809590B2/en not_active Expired - Fee Related
- 2015-10-19 JP JP2015205806A patent/JP2016040303A/ja not_active Withdrawn
-
2016
- 2016-09-02 AU AU2016222468A patent/AU2016222468B2/en not_active Ceased
-
2017
- 2017-09-27 US US15/717,700 patent/US10669269B2/en not_active Expired - Fee Related
- 2017-11-27 JP JP2017227134A patent/JP2018065835A/ja not_active Withdrawn
-
2018
- 2018-03-16 AU AU2018201903A patent/AU2018201903B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA112425C2 (uk) | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ | |
| UA108222C2 (xx) | СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS | |
| CY1120154T1 (el) | Παραγωγα πιπεριδιν-4-υλ αζετιδινης ως αναστολεις jak1 | |
| NI201200072A (es) | Métodos y composiciones para tratar cáncer | |
| IN2014DN09352A (https=) | ||
| IN2014DN09348A (https=) | ||
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| UA114421C2 (uk) | Кристалічна форма інгібітору тирозинкінази брутона | |
| UA116774C2 (uk) | Інгібітори серин/треонінкінази | |
| EA201300684A1 (ru) | Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1 | |
| EA201101243A1 (ru) | 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| MX2015017964A (es) | Inhibidores de bromodominio. | |
| MY156727A (en) | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| IN2014DN09347A (https=) | ||
| WO2011150201A3 (en) | Azolyl amide compounds and methods of use thereof | |
| IN2013DN02555A (https=) | ||
| MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
| EA201400786A1 (ru) | Карбоциклические нуклеозиды, их фармацевтическое применение и композиции | |
| CY1116345T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ Ν-(1Η-ΙΝΔΑΖΟΛ-4-ΥΛ)ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΟ-3-ΚΑΡΒΟΞΑΜΙΔΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ ΥΠΟΔΟΧΕΑ ΤΥΠΟΥ III | |
| EA201390619A1 (ru) | 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения | |
| CY1115468T1 (el) | Ενωσεις υποκατεστημενου ν-(1η-ινδαζολ-4υλ)ιμιδαζο[1,2-α]πυριδινο-3-καρβοηαμιδιου ως αναστολεις cfms | |
| UA110108C2 (xx) | Азетидинові похідні піперидин-4-ілу як інгібітори jak1 | |
| EA201890558A1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 |